National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 1) (No. PB 4 of 2014) (Cth)

PB 4 of 2014

National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 1)

National Health Act 1953

___________________________________________________________________________

I, LAURA TOYNE, Acting Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the

National Health Act 1953.

Dated   23 January 2014

LAURA TOYNE

Acting Assistant Secretary

Pharmaceutical Access Branch

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________________

1       Name of Instrument

(1)This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No.1).

(2)This Instrument may also be cited as PB 4 of 2014.

2              Commencement

This Instrument commences on 1 February 2014.

3              Amendments to PB 116 of 2010

Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).

Schedule 1       Amendments

Section 3

[1]     Schedule 1, entry for Pamidronic Acid in the form Concentrated injection containing disodium pamidronate 15 mg in 5 mL with manner of administration Injection and brand Pamisol

Omit from the column headed ‘Circumstances’: C1500 C3341              Substitute: C4430 C4433

[2]     Schedule 1, entry for Pamidronic Acid in the form Concentrated injection containing disodium pamidronate 30 mg in 10 mL with manner of administration Injection and brand Pamisol

Omit from the column headed ‘Circumstances’: C1500 C3341              Substitute: C4424 C4425

[3]     Schedule 1, entry for Pamidronic Acid in the form Injection set containing 2 vials powder for I.V. infusion containing disodium pamidronate 30 mg and 2 ampoules solvent 10 mL manner of administration Injection and brand Aredia 30mg

Omit from the column headed ‘Circumstances’: C1500 C3341             Substitute: C4424 C4425

[4]     Schedule 1, entry for Pamidronic Acid in the form Concentrated injection containing disodium pamidronate 60 mg in 10 mL with manner of administration Injection and brand Pamisol

Omit from the column headed ‘Circumstances’: C1500 C3341              Substitute: C4430 C4433

[5]     Schedule 1, entry for Pamidronic Acid in the form Concentrated injection containing disodium pamidronate 90 mg in 10 mL with manner of administration Injection and brand Pamisol

Omit from the column headed ‘Circumstances’: C1035 C1233 C1500 C3341 C3342 C3343

Substitute: C4421 C4426 C4428 C4429 C4431 C4432

[6]     Schedule 1, entry for Pamidronic Acid in the form Injection set containing 1 vial powder for I.V. infusion containing disodium pamidronate 90 mg and 1 ampoule solvent 10 mL manner of administration Injection and brand Aredia 90mg

Omit from the column headed ‘Circumstances’: C1035 C1233 C1500 C3341 C3342 C3343

Substitute: C4421 C4426 C4428 C4429 C4431 C4432

[7]     Schedule 3, entry for Pamidronic Acid

Substitute:

Pamidronic Acid	C4421	Where the patient is receiving treatment at/from a public hospital Hypercalcaemia of malignancy Patient must have a malignancy refractory to anti-neoplastic therapy	Compliance with Written and Telephone Authority Required procedures –  Streamlined Authority Code 4421
C4424	Where the patient is receiving treatment at/from a private hospital Hypercalcaemia of malignancy Patient must have a malignancy refractory to anti-neoplastic therapy	Compliance with Written and Telephone Authority Required procedures
C4425	Where the patient is receiving treatment at/from a public hospital Hypercalcaemia of malignancy Patient must have a malignancy refractory to anti-neoplastic therapy	Compliance with Written and Telephone Authority Required procedures –  Streamlined Authority Code 4425
C4426	Where the patient is receiving treatment at/from a public hospital Bone metastases The condition must be due to breast cancer	Compliance with Written and Telephone Authority Required procedures – Streamlined Authority Code 4426
C4428	Where the patient is receiving treatment at/from a private hospital Hypercalcaemia of malignancy Patient must have a malignancy refractory to anti-neoplastic therapy	Compliance with Written and Telephone Authority Required procedures
C4429	Where the patient is receiving treatment at/from a private hospital Bone metastases The condition must be due to breast cancer	Compliance with Written and Telephone Authority Required procedures
C4430	Where the patient is receiving treatment at/from a private hospital Hypercalcaemia of malignancy Patient must have a malignancy refractory to anti-neoplastic therapy	Compliance with Written and Telephone Authority Required procedures
C4431	Where the patient is receiving treatment at/from a private hospital Multiple myeloma	Compliance with Written and Telephone Authority Required procedures
C4432	Where the patient is receiving treatment at/from a public hospital Multiple myeloma	Compliance with Written and Telephone Authority Required procedures – Streamlined Authority Code 4432
C4433	Where the patient is receiving treatment at/from a public hospital Hypercalcaemia of malignancy Patient must have a malignancy refractory to anti-neoplastic therapy	Compliance with Written and Telephone Authority Required procedures –  Streamlined Authority Code 4433